Strategic acquisition expands Ceva’s intestinal health portfolio, accelerates vaccine innovation and supports reduced antibiotic use in pig production.
Ceva Expands Swine Disease Prevention Through Strategic Acquisition
Ceva Animal Health has strengthened its position in the global swine health market through the acquisition of Aquilón CyL S.L., a Spanish biotechnology company specializing in research, diagnostics and biological solutions for pig diseases. The acquisition gives Ceva access to Europe’s first and only commercial vaccine against swine dysentery caused by Brachyspira hyodysenteriae, reinforcing its commitment to preventive animal health and sustainable pig production.
The acquisition is widely regarded as one of the most significant developments in the European swine health sector this year because it combines an innovative commercial vaccine with a highly specialized scientific team focused on intestinal diseases in pigs.
Why Aquilón Matters
Founded in 2012 as a spin-off from the University of León in Spain, Aquilón has spent more than a decade translating academic research into practical veterinary solutions for commercial pig production. The company has developed expertise in:
-
Swine intestinal diseases
-
Veterinary diagnostics
-
Biological disease prevention
-
Vaccine development
-
Pig gut health research
Its flagship achievement is Biobhyo®, the first commercially available vaccine in Europe designed to protect pigs against swine dysentery caused by Brachyspira hyodysenteriae.
For Ceva, the acquisition adds not only a unique vaccine but also specialized research capabilities that can strengthen its future swine innovation pipeline.
Swine Dysentery Remains a Major Global Production Challenge
Swine dysentery is a contagious bacterial disease affecting the large intestine of pigs. It is caused primarily by Brachyspira hyodysenteriae and remains one of the most economically important enteric diseases in commercial pig production.
Clinical signs include:
-
Severe mucohaemorrhagic diarrhoea
-
Reduced feed intake
-
Poor weight gain
-
Dehydration
-
Increased mortality in severe outbreaks
Even when mortality is limited, the disease can significantly reduce growth performance and increase production costs through medication, labour and delayed market weights.
Prevention Is Becoming More Important Than Treatment
Modern pig production is increasingly shifting from disease treatment to disease prevention. Many countries have introduced antimicrobial stewardship programmes that encourage livestock producers to reduce routine antibiotic use while maintaining high standards of animal health and welfare.
Vaccination has therefore become an increasingly important tool because it can:
-
Reduce disease incidence
-
Improve animal welfare
-
Lower production losses
-
Minimise antibiotic use
-
Support sustainable farming practices
Ceva’s acquisition directly aligns with this global trend by expanding preventive options for veterinarians and pig producers.
Strengthening Ceva’s Intestinal Health Portfolio
Ceva already has a strong presence in livestock vaccines and preventive medicine. By integrating Aquilón, the company significantly strengthens its expertise in swine intestinal health, an area receiving growing attention because digestive diseases remain among the leading causes of economic loss in pig farming.
According to Ceva, the acquisition will help accelerate:
-
Development of next-generation vaccines
-
New diagnostic technologies
-
Research into pig gut health
-
Improved disease surveillance
-
Sustainable disease prevention programmes
The transaction also supports Ceva’s long-term strategy of combining scientific innovation with practical on-farm disease control solutions.
Scientific Expertise Joins Ceva’s Global R&D Network
One of the most valuable aspects of the acquisition is the integration of Aquilón’s scientific team into Ceva’s global research organisation. Researchers with extensive experience in pig intestinal microbiology, diagnostics and vaccine development will now contribute to Ceva’s international R&D programmes.
This collaboration is expected to accelerate innovation in:
-
Enteric disease vaccines
-
Diagnostic assays
-
Precision disease monitoring
-
Preventive health technologies
The combination of academic expertise and Ceva’s global commercial network may also increase access to these technologies in additional international markets over time.
Supporting Reduced Antibiotic Use
Livestock industries worldwide are under increasing pressure to reduce antibiotic consumption while maintaining productivity. Vaccines are considered one of the most effective preventive tools because they reduce the likelihood of disease outbreaks before antimicrobial treatment becomes necessary.
By adding a vaccine specifically targeting swine dysentery, Ceva strengthens its ability to support:
-
Responsible antimicrobial stewardship
-
Improved herd health
-
Better production efficiency
-
Sustainable pig farming
These objectives align closely with veterinary public health strategies promoted across Europe and many other livestock-producing regions.
A Competitive Advantage in the European Swine Market
The acquisition also provides Ceva with an important competitive advantage. Unlike many acquisitions that primarily add manufacturing capacity or geographic reach, this transaction adds a differentiated product with limited direct competition.
Europe’s commercial swine industry continues to invest heavily in:
-
Biosecurity
-
Disease prevention
-
Precision livestock management
-
Vaccine-based health programmes
Adding the continent’s only commercial swine dysentery vaccine positions Ceva to play a larger role in these evolving production systems.
Industry Significance
The acquisition reflects broader trends shaping the global animal health industry:
-
Increased investment in livestock vaccines.
-
Growing emphasis on preventive medicine.
-
Continued reduction in routine antibiotic use.
-
Expansion of precision diagnostics.
-
Stronger collaboration between biotechnology companies and multinational animal health firms.
As disease prevention becomes increasingly central to livestock production, strategic acquisitions that combine innovative science with commercial scale are expected to become more common.
Outlook
Ceva’s acquisition of Aquilón represents more than a portfolio expansion—it strengthens the company’s scientific capabilities in one of the most important areas of modern pig production. With the addition of Europe’s only commercial vaccine against swine dysentery, expanded expertise in intestinal health and a stronger research platform, Ceva is well positioned to support veterinarians and pig producers seeking more effective, preventive approaches to disease management.
For the global swine industry, the transaction highlights a continuing shift toward vaccination, precision diagnostics and sustainable disease prevention, reinforcing the growing importance of innovation in improving animal health, farm productivity and responsible antibiotic stewardship.
